Semaglutide Safety Signal: Poison Control Data Reveals True Adverse Event Burden

The Semaglutide Safety Blind Spot

When the FDA approved semaglutide (Ozempic, Wegovy) for chronic weight management in June 2021, the label carried the expected adverse event profile: nausea, vomiting, diarrhea, pancreatitis risk, and thyroid C-cell concerns from rodent studies. What wasn't anticipated was the signal that would emerge from an unconventional data source: poison control centers.

A UT San Antonio study analyzing National Poison Data System (NPDS) records found that calls related to semaglutide exposure skyrocketed in the months and years following FDA approval. This finding exposes a critical gap in our pharmacovigilance infrastructure: traditional adverse event reporting (FDA MedWatch, spontaneous reporting) systematically underdetects harm that prompts emergency intervention.

Why Poison Control Data Matters

The poison control system captures a different denominator than conventional AE reporting. When a patient experiences severe nausea, uncontrollable vomiting, or suspected acute pancreatitis after a semaglutide injection, they often call Poison Control before—or instead of—contacting their prescriber. This creates a parallel surveillance stream that's less subject to:

• Reporting bias: Patients who experience minor AEs don't call Poison Control; they call their doctor—or don't report at all
• Attribution lag: Traditional reporting requires the patient to connect the symptom to the drug; Poison Control receives calls in real-time during acute events
• Provider gatekeeping: Poison Control data is captured directly from patient calls, bypassing potential underreporting by prescribers

The NPDS data essentially captures the "iceberg tip" of acute, serious enough events that required emergency guidance.

What the Numbers Show

While the specific data from the UT San Antonio study warrants detailed review, the spike in poison control calls post-approval aligns with what we've observed clinically:

1. Gastrointestinal toxicity severity: Semaglutide-induced nausea and vomiting can be profound enough to cause dehydration, electrolyte abnormalities, and aspiration risk—all reasons to call Poison Control
2. Dosing escalation problems: Patients who escalate too quickly or use compounded formulations of variable concentration experience more severe GI effects
3. Drug-drug interactions: Semaglutide slows gastric emptying, potentially increasing absorption of other medications or creating unexpected toxicity patterns
4. Pancreatitis signal: Acute abdominal pain with nausea/vomiting triggers emergency evaluation; some of these calls likely involved suspected pancreatitis

The Mechanism: GLP-1 Receptor Activation in the Gut and Beyond

Semaglutide works via GLP-1 receptor agonism, activating receptors throughout the gastrointestinal tract and brainstem. While this produces the desired appetite suppression, it also:

• Delays gastric emptying significantly (can worsen existing gastroparesis)
• Stimulates nausea via chemoreceptor trigger zone activation
• May increase pancreatic enzyme secretion in susceptible individuals
• Affects fluid secretion in the intestines

At doses >1.0 mg weekly, these effects intensify. Compounded formulations—increasingly popular due to cost and access—often lack the pharmaceutical-grade stability and sterile manufacturing of FDA-approved products, potentially exacerbating adverse events.

Clinical Implications for Prescribers

This safety signal suggests several actionable practices:

1. Baseline labs matter: Lipase, amylase, comprehensive metabolic panel (electrolytes, renal function), and liver function tests should be obtained before starting semaglutide
2. Slow titration is non-negotiable: Starting at 0.25 mg and escalating no faster than every 4 weeks (ideally 6 weeks in older patients) reduces AE severity
3. Patient education on red flags: Persistent severe vomiting, epigastric pain, or signs of dehydration warrant immediate evaluation, not home management
4. Medication reconciliation: Semaglutide delays gastric emptying; medications requiring gastric absorption (some antibiotics, bisphosphonates) may need timing adjustments
5. Avoid compounded formulations when possible: Stick with FDA-approved semaglutide products (Ozempic, Wegovy) when accessible; they have consistent potency and sterility

The Broader Pharmacovigilance Lesson

This study exemplifies why single-source adverse event monitoring is insufficient. The FDA's MedWatch system, while essential, depends on voluntary reporting and captures only a fraction of serious events. Poison control data, insurance claims data, and emergency department surveillance all provide complementary information.

For a drug being used off-label at doses exceeding FDA-approved levels—and semaglutide is increasingly prescribed for diabetes and weight loss in non-approved populations—multiple surveillance channels become critical.

Bottom Line

The UT San Antonio poison control signal is a legitimate safety concern that warrants:

• Detailed pharmacovigilance review of the specific cases to identify patterns (e.g., dose-response, patient characteristics associated with severe toxicity)
• FDA communication to prescribers about appropriate dosing, baseline labs, and patient selection
• Provider awareness that semaglutide's safety profile is narrow, and slow titration with robust baseline and follow-up testing is non-negotiable
• Patient transparency about real-world adverse event rates, especially for individuals using compounded formulations

Semaglutide is effective for weight loss and glycemic control, but its benefit-risk profile is unfavorable in patients with pre-existing GI disease, pancreatic risk factors, or those unable to tolerate titration. The poison control spike suggests we've been underestimating how many patients fall into the "can't tolerate" category.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.